Partnership for Research on Ebola VACcinations (PREVAC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02876328

Recruitment Status : Active, not recruiting

First Posted : August 23, 2016

Last Update Posted : July 29, 2020

Sponsor:

Collaborators:

Partnership for Research on Ebola Virus in Liberia (PREVAIL)

Institut National de la Santé Et de la Recherche Médicale, France

London School of Hygiene and Tropical Medicine

European and Developing Countries Clinical Trials Partnership (EDCTP)

Information provided by (Responsible Party):

National Institute of Allergy and Infectious Diseases (NIAID)

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	January 31, 2021
Estimated Study Completion Date :	June 2024

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Badio M, Lhomme E, Kieh M, Beavogui AH, Kennedy SB, Doumbia S, Leigh B, Sow SO, Diallo A, Fusco D, Kirchoff M, Termote M, Vatrinet R, Wentworth D, Esperou H, Lane HC, Pierson J, Watson-Jones D, Roy C, D'Ortenzio E, Greenwood B, Chêne G, Richert L, Neaton JD, Yazdanpanah Y; PREVAC study team. Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries. Trials. 2021 Jan 23;22(1):86. doi: 10.1186/s13063-021-05035-9.

To Top